APLUSA’s Post

“Empowering Health: SGLT2 Inhibitors like Empagliflozin and Dapagliflozin are leading the charge against Cardiovascular-Kidney Metabolic Syndrome. Grateful for the knowledge gained at the session on transforming diabetes, heart failure, and CKD management. Ready to make a positive impact in patient care! #MedicalEducation #ContinuousLearning #HealthcareInnovation #CardiovascularHealth #KidneyFunction”

Discover how advanced technology empowers young patients with type 1 diabetes to live more freely and enjoy a higher quality of life at the Tandem Diabetes Care symposium. + Proven clinical results of Control-IQ technology + Personalized treatment to help optimize outcomes for young patients + Future innovations that focus on greater ease of use Experience the difference and help patients thrive. "Let the Kids Be Kids: Optimizing Diabetes Care with Control-IQ Technology” 🗓️Thursday 17 October 🕚 08:00-09:00 am 📍 Session Hall 2: Auditorium VIII #ISPAD2024 #DiabetesAwareness #DiabetesTechnology #TandemDiabetes #tslimX2 This product may not be right for you. Always read and follow the label. Indicated for patients with type 1 diabetes, 6 years and older. WARNING: Control-IQ technology should not be used by people under age 6, or who use less than 10 units of insulin/day, or who weigh less than 25 kilograms. Safety info: https://lnkd.in/d3SmUSb

Our first Institutional Insights video series is now available! Dive into "Empowering Early Intervention: Navigating Treatments for Delaying T1D Progression," featuring insights from Albany Medical Center. Explore teplizumab's pivotal role in delaying type 1 diabetes progression, understand disease staging, screening protocols, and much more. Watch now to make a difference in diabetes management. https://lnkd.in/eVDU5JrZ

It's time to explore the transformative power of patient-centric approaches in diabetes trials! Learn how integrating eCOA and positive reinforcement can enhance participant retention and improve trial outcomes. Dive in for insights: https://hubs.li/Q02jff0m0 #eCOA #patientcentricity #patientengagement #clinicaltrials

Our first Institutional Insights video series at Patient Care Online is now available! Dive into "Empowering Early Intervention: Navigating Treatments for Delaying T1D Progression," featuring insights from Albany Medical Center. Explore teplizumab's pivotal role in delaying type 1 diabetes progression, understand disease staging, screening protocols, and much more. Watch now to make a difference in diabetes management: https://lnkd.in/dTfvcfNt

How does Breakthrough T1D aid in preventing a misdiagnosis for individuals with Type 1 or Type 2 Diabetes? Avoiding a misdiagnosis when you’re an individual with diabetes is crucial. Dr. Jeremy Pettus, Dr. Steve Edelman, and Dr. Aaron Kowalski, CEO of Breakthrough T1D discuss how Breakthrough T1D approaches misdiagnosis prevention for individuals with diabetes, what can be done, what they can do, and how they can help prevent this from happening in the future. Have you or a loved one been misdiagnosed with type 2 diabetes when it was really type 1? Stay tuned! Whether you're a healthcare professional or concerned about your own diagnosis, we will be releasing more videos that will provide crucial insights to ensure accurate T1D identification at any age. Don't miss this vital information that could change lives.

There are some super exciting updates in T1 Diabetes on this podcast from Dr. Edelman and Anastasia Albanese-O'Neill that I highly recommend. A couple of compelling reasons to screen early that stood out to me is that 80% of peope living with type 1 diabetes are the first diagnosed in their family but those family members are at 15X higher risk of being diagnosed in the future. Secondly, new therapies have emerged with additional ones in the pipeline that can delay the onset of insulin by 2-3 years on average! Key takeaway: We are entering a new era not only in management and prevention but in how we think about the disease and the broader connection to other auto-immune diseases like thyroid, Crohn's, and celiac, etc. There are so many more reasons to get screened than I realized!

 Our first Institutional Insights video series is now available! "Empowering Early Intervention: Navigating Treatments for Delaying T1D Progression," features insights from experts in diabetes management from Albany Medical Center who are using teplizumab with young patients to delay progression of type 1 diabetes from type 1 stage 2 to type 1 stage 3, or frank diabetes. They discuss type 1 diabetes screening, staging, and appropriate follow-up; explore the teplizumab mechanism of action; look at location options for infusion, and more.   https://lnkd.in/eiymhTgN

Our latest work on GLP1-RA in diabetics with MASLD. In this real-life cohort of patients with diabetes and MASLD, treatment with GLP-1RA was associated with greater weight loss and hepatic fat reduction, but a reduction in fat content was also observed in patients who did not lose weight. Check this out 👇 https://lnkd.in/ghPyb_5E

In this video, Kathryn Kreider, DNP, APRN, FAANP, FNP-BC, speaks about how clinicians can individualize care for their patients with type 2 diabetes, including strategies that can be used, what clinicians should consider when creating an individualized care plan, and what current barriers exist for patients with type 2 diabetes. Watch the full video here: https://okt.to/PHzgA3